



4/1
FULBRIGHT & JAWORSKI L.L.P.


A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

1640
RECEIVED
NOV 10 2003
TECH CENTER 1500/2000

SHIGHLANDER@FULBRIGHT.COM
PARTNER
DIRECT DIAL: (512) 536-3184

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

November 3, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
<u>November 3, 2003</u> Date	 Steven L. Highlander


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: *U.S. Serial No. 09/852,587 Entitled: "PREVENTION OF INSULIN-DEPENDENT DIABETES, COMPLICATIONS THEREOF, OR ALLOGRAFT REJECTION BY INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY" by Tahereh Tabatabaie et al.*
(Client Ref. 2000-004-002)
Our Ref. No. OMRF:008US / Matter No. 10112237

Enclosed for filing in the above-referenced patent application is:

1. Response to Restriction Requirement Dated October 3, 2003;
2. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/OMRF:008US/SLH.


Very truly yours,

Steven L. Highlander

SLH/cpj
Encl: As noted

25353485.1




RECEIVED
NOV 10 2003
TECH CENTER 1600/2300

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date below:

November 3, 2003
Date


Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tahereh Tabatabaie and
Yashige Kotake

Serial No.: 09/852,587

Filed: May 10, 2001

For: PREVENTION OF INSULIN-
DEPENDENT DIABETES,
COMPLICATIONS THEREOF, OR
ALLOGRAFT REJECTION BY
INHIBITION OF CYCLOOXYGENASE-2
ACTIVITY

Group Art Unit: 1640

Examiner: Shahnman J. Sharareh

Atty. Dkt. No.: OMRP:008US/SLH

RESPONSE TO RESTRICTION REQUIREMENT DATED OCTOBER 3, 2003

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Commissioner:

This paper is submitted in response to the Restriction Requirement dated October 3, 2003 for which the date for response is November 3, 2003.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/OMRF:008US/SLH.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1-7, 10-13, 15-23, *i.e.*, the Group 1 claims.

The Examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven D. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: 11/3/03